Talha Munir overviews the performance of next-generation BTK inhibitors like zanubrutinib in treating CLL, highlighting their efficacy and safety compared to older BTK inhibitors while further explaining the concept of matching-adjusted indirect comparison and its importance in future research. Lastly, he discusses how next-generation BTK inhibitors impact quality of life and their economic implications in B-cell malignancies.

Here is the full EHA 2024 report.